Mizutani Y, Okada Y, Yoshida O, Bonavida B
Department of Urology, Faculty of Medicine, Kyoto University, Japan.
Cancer Biother Radiopharm. 1996 Dec;11(6):385-91. doi: 10.1089/cbr.1996.11.385.
Cell-mediated immunity is an important and central mechanism of host resistance to cancer. Most reported studies have used cultured tumor cell lines as targets to assess antitumor cell-mediated cytotoxicity. However, it is difficult to translate the data generated from the cytotoxic activity against cultured tumor cell lines to cytotoxicity against autologous tumors. In a recent study, we have reported on the prognostic significance of circulating cytotoxic lymphocytes against autologous tumor cells in patients with bladder cancer. In this study, we examined whether established bladder cancer cell line like T24 or NK-sensitive K562 target cells can be substituted for autologous bladder cancer cells. The cytotoxic activity of peripheral blood lymphocytes (PBL) against freshly isolated autologous tumor cells, the T24 human bladder cancer cell line and the NK-sensitive K562 human myelogenous leukemia cell line was studied in 63 patients with primary initial bladder cancer by a 12-h 51Cr release assay. The mean percent cytotoxic activity of PBL directed against autologous tumor cells, T24 cells and K562 cells were 11.3%, 18.2% and 29.4%, respectively, using an E:T of 40:1. The cytotoxic activity against T24 cells in patients with bladder cancer was higher than that in normal individuals. The anti-K562 and the anti-T24 cytotoxic activities in patients with low-stage or low-grade bladder cancer were relatively higher than those in patients with high-stage or high-grade cancer, but not statistically significant. There was no correlation between the anti-autologous tumor cytotoxic activity and either the histologic grade or stage in patients with bladder cancer. The extent of the anti-autologous tumor cytotoxic activity was not paralleled with that of either the anti-K562 or the anti-T24 cytotoxic activity. In contrast, the anti-K562 cytotoxic activity correlated positively with the anti-T24 cytotoxic activity. Separation of PBL revealed that the anti-K562 and the anti-T24 cytotoxic activities were mediated mainly by the NK cells, whereas the anti-autologous tumor cytotoxic activity was mediated by both the NK cells and the T lymphocytes. These findings demonstrate that cytotoxicity against T24 or K562 cells is not of prognostic value. The magnitude of the anti-autologous tumor cytotoxic activity of PBL derived from bladder cancer patients might represent an independent and important immunological parameter to monitor disease progression.
细胞介导的免疫是宿主抵抗癌症的重要核心机制。大多数已报道的研究使用培养的肿瘤细胞系作为靶标来评估抗肿瘤细胞介导的细胞毒性。然而,很难将针对培养肿瘤细胞系的细胞毒性活性所产生的数据转化为针对自体肿瘤的细胞毒性。在最近的一项研究中,我们报道了膀胱癌患者循环细胞毒性淋巴细胞对自体肿瘤细胞的预后意义。在本研究中,我们检测了像T24这样的既定膀胱癌细胞系或NK敏感的K562靶细胞是否可以替代自体膀胱癌细胞。通过12小时51Cr释放试验,在63例原发性初发膀胱癌患者中研究了外周血淋巴细胞(PBL)对新鲜分离的自体肿瘤细胞、T24人膀胱癌细胞系和NK敏感的K562人骨髓白血病细胞系的细胞毒性活性。使用40:1的效靶比(E:T)时,PBL针对自体肿瘤细胞、T24细胞和K562细胞的平均细胞毒性活性百分比分别为11.3%、18.2%和29.4%。膀胱癌患者针对T24细胞的细胞毒性活性高于正常个体。低分期或低分级膀胱癌患者的抗K562和抗T24细胞毒性活性相对高于高分期或高分级癌症患者,但无统计学意义。膀胱癌患者的抗自体肿瘤细胞毒性活性与组织学分级或分期之间均无相关性。抗自体肿瘤细胞毒性活性的程度与抗K562或抗T24细胞毒性活性的程度均不平行。相反,抗K562细胞毒性活性与抗T24细胞毒性活性呈正相关。PBL的分离显示,抗K562和抗T24细胞毒性活性主要由NK细胞介导,而抗自体肿瘤细胞毒性活性由NK细胞和T淋巴细胞共同介导。这些发现表明,针对T24或K562细胞的细胞毒性没有预后价值。膀胱癌患者来源的PBL的抗自体肿瘤细胞毒性活性大小可能代表一个独立且重要的免疫参数,用于监测疾病进展。